Uppsala, Sweden, 2011-03-02 09:15 CET (GLOBE NEWSWIRE) -- Initial production of launch quantities of Paccal® Vet will be carried out at Oasmia Pharmaceutical’s own facility in Uppsala, while technology and knowledge is transferred to Baxter.
- This is an important step for Oasmia’s future growth. Baxter is a very strong partner and enables us to meet the global demand we know exists in the market for Paclical® and Paccal® Vet, says Julian Aleksov, CEO of Oasmia Pharmaceutical AB.
The agreement may also be expanded to include other product candidates from Oasmia product portfolio.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company was registered in 1999 and is located in Uppsala, Sweden.
Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. German contact : Axel Mühlhaus, edicto GmbH, Frankfurt E-Mail: oasmia@edicto.de Phone: +49 (0) 69 90 55 05 52. Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de
